Iannantuoni, Francesca <br/><br/>
The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes.  [electronic resource] 

 -  Journal of clinical medicine  Nov 2019 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>2077-0383 
<br/><br/><label>Standard No.: </label>10.3390/jcm8111814  doi